Skip to main content
SpringerLink
Log in

Molecular Analysis of the PTEN, TP53 and CDKN2A Tumor Suppressor Genes in Long-term Survivors of Glioblastoma Multiforme

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Despite multimodal therapy, glioblastoma multiforme (GBM) is associated with a poor prognosis with a median survival of less than 1 year. However, a small number of patients with GBM shows survival times of several years. Although clinical features like age and performance status at diagnosis are well known prognostic parameters, molecular markers for prognosis of overall survival are still lacking. Therefore, we compared 2 age- and gender-matched groups of GBM patients with different post-operative time to tumor progression (TTP), defined as 'short-term' for TTP of less than 6 months (n=21), and 'long-term' for TTP of more than 24 months (n=21) for genetic alterations of the PTEN, CDKN2A and TP53 genes as well as overexpression of the EGFR, p53 and Mdm2 proteins. For the GBMs with 'short-term' TTP vs. 'long-term' TTP, the studies revealed PTEN mutations in 4/21 vs. 2/21, TP53 mutations in 5/21 vs. 8/21, homozygous deletion of the CDKN2A gene in 5/21 vs. 6/21, overexpression of EGFR in 7/20 vs. 10/20, accumulation of p53 protein in 9/20 vs. 7/20 and of Mdm2 protein in 0/20 vs. 1/20 cases studied. Taken together, our data indicate that mutations of the PTEN and TP53 tumor suppressor genes, homozygous deletion of the CDKN2A gene as well as overexpression of the EGFR, p53 and Mdm2 proteins lack prognostic significance for overall survival time in patients with GBMs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lantos PL, VandenBerg SR, Kleihues P: Tumours of the nervous system. In: Graham DI, Lantos PL (eds) Greenfield's Neuropathology. 6th edn. Arnold, 1997, pp 600-626

  2. Imperato JP, Paleologos NA, Vick NA: Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28: 818-822, 1990

    Google Scholar 

  3. Forsyth PA, Cairncross JG: Treatment of malignant glioma in adults. Curr Opin Neurol 8: 414-418, 1995

    Google Scholar 

  4. Salford L, Brun A, Nirfalk S: Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69: 506-509, 1988

    Google Scholar 

  5. Chandler KL, Prados MD, Malec M, Wilson CB: Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993

    Google Scholar 

  6. Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR: Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro-Oncol 27: 259-266, 1996

    Google Scholar 

  7. Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P: Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci 25: 197-201, 1998

    Google Scholar 

  8. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993

    Google Scholar 

  9. Devaux BC, O'Fallon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78: 767-775, 1993

    Google Scholar 

  10. Collins VP: Progression as exemplified by human astrocytic tumors. Semin Cancer Biol 9: 267-276, 1999

    Google Scholar 

  11. Rasheed BKA, Wiltshire RN, Bigner SH, Bigner DD: Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11: 162-167, 1999

    Google Scholar 

  12. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997

    Google Scholar 

  13. Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107, 1999

    Google Scholar 

  14. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993

    Google Scholar 

  15. Duerr E-M, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16: 2259-2264, 1998

    Google Scholar 

  16. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WKA, Steck PA: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 4: 2447-2454, 1998

    Google Scholar 

  17. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN: Malignant astrocytomas with homozygousCDKN2gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 55: 1026-1031, 1996

    Google Scholar 

  18. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A: Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871-875, 1997

    Google Scholar 

  19. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. In: Kleihues P, Burger PC, Scheithauer BW (eds) International Histological Classification of Tumors. World Health Organization, Geneva, 1993

    Google Scholar 

  20. Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster F, Baumann A, Schlegel U: TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10: 143-149, 1994

    Google Scholar 

  21. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54: 91-95, 1995

    Google Scholar 

  22. Riemenschneider MJ, Büschges R, Wolter M, Reifenberger J, Boström J, Kraus JA, Schlegel U, Reifenberger G: Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091-6096, 1999

    Google Scholar 

  23. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blümcke I, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg 85: 634-641, 1996

    Google Scholar 

  24. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefit from adjuvant chemotherapy? Ann Neurol 44: 691-695, 1998

    Google Scholar 

  25. Vertosick FT, Selker RG: Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 38: 359-363, 1992

    Google Scholar 

  26. Salcman M, Scholtz H, Kaplan RS, Kulik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994

    Google Scholar 

  27. Olivera C, Bartley M, Ferrall S, Phuphanich S: Long-term malignant glioma survivors over ten years: prognostic factors. Proceedings of ASCO16: 407a, 1997 (Abstr)

  28. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperation Oncology Group study. Cancer 52: 997-1007, 1983

    Google Scholar 

  29. Coffey RJ, Lunsford LD, Taylor FH: Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22: 465-473, 1988

    Google Scholar 

  30. Shapiro WR, Green SB, Burger PC, Mahaley MS, Selker RG, van Gilder JC, Robertson JT, Ransohoff J, Mealey J, Strike TA, Pistenmaa DA: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 71: 1-9, 1989

    Google Scholar 

  31. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34: 45-60, 1994

    Google Scholar 

  32. Weber RG, Sommer C, Albert FK, Kiessling M, Cremer T: Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. Lab Invest 74: 108-119, 1996

    Google Scholar 

  33. Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD: Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 13: 717-724, 1998

    Google Scholar 

  34. James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, Olson JJ, Scheithauer BW: Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol 15: 547-553, 1999

    Google Scholar 

  35. Rasheed BKA, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187-4190, 1997

    Google Scholar 

  36. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: Somatic mutations ofPTEN in glioblastoma multiforme Cancer Res 57: 4183-4186, 1997

    Google Scholar 

  37. Boström J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29-33, 1998

    Google Scholar 

  38. Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP: Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 58: 1170-1183, 1999

    Google Scholar 

  39. Pardo FS, Hsu DW, Hedley-Whyte ET, Efird J, Schmidt EV: High p53 expression is prognostic of overall survival in adult supratentorial astrocytoma patients. J Neuro-Oncol 15 (Suppl): S19, 1993

    Google Scholar 

  40. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994

    Google Scholar 

  41. Rasheed BKA, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH: Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330, 1994

    Google Scholar 

  42. Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJ: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79: 159-165, 1998

    Google Scholar 

  43. Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1: 44-51, 1999

    Google Scholar 

  44. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1995

    Google Scholar 

  45. Ueki K, Onon Y, Henson JW, von Deimling A, Louis DN: CDKN2 or RB alterations occur in the majority of glioblastomas and are inversely related. Cancer Res 56: 150-153, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Bonn Medical Center, Bonn, Germany

    Jürgen A. Kraus, Nicole Glesmann, Martina Beck, Thomas Klockgether & Uwe Schlegel

  2. Department of Neurosurgery, University of Dresden, Dresden, Germany

    Dietmar Krex & Gabriele Schackert

Authors
  1. Jürgen A. Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole Glesmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martina Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dietmar Krex
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Klockgether
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriele Schackert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Uwe Schlegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kraus, J.A., Glesmann, N., Beck, M. et al. Molecular Analysis of the PTEN, TP53 and CDKN2A Tumor Suppressor Genes in Long-term Survivors of Glioblastoma Multiforme. J Neurooncol 48, 89–94 (2000). https://doi.org/10.1023/A:1006402614838

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006402614838

Search

Navigation